Ireland granted SPC for Galliprant® on December 17, 2019, a veterinary drug product developed and marketed by Elanco Animal Health Inc. (Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until February 28, 2031. Additional SPCs for Galliprant® are currently under examination in several major EU countries. The grant in Ireland marks the sixth approval in the EU, following grants received in Italy, Holland, Spain, Germany, and France.

Galliprant®
Galliprant® (grapiprant tablets) is a prostaglandin E2 (PGE2) EP4 receptor antagonist for the control of pain and inflammation associated with osteoarthritis in dogs. Elanco is currently marketing Galliprant® in the US and several EU countries.

Supplementary Protection Certificate (SPC)
In major countries around the world, a patent generally expires after 20 years following submission of the patent application. However, the patent exclusivity periods for pharmaceuticals may be extended for a maximum of five years in order to compensate for the time consuming and costly research and development. The SPC grant by Ireland for Galliprant® represents a five-year extension of the therapy’s exclusive sales period.